<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39355387</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1949-8470</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>World journal of radiology</Title><ISOAbbreviation>World J Radiol</ISOAbbreviation></Journal><ArticleTitle>Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report.</ArticleTitle><Pagination><StartPage>489</StartPage><EndPage>496</EndPage><MedlinePgn>489-496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4329/wjr.v16.i9.489</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">According to the population statistics in 2023, there were 110000 people aged over 100 years in China, and the experience of using Paxlovid (nirmatrelvir/ritonavir) for centenarians is particularly valuable. This article reports our experience of using Paxlovid in a centenarian with the novel coronavirus disease 2019 (COVID-19) infection.</AbstractText><AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 103-year-old female with mild COVID-19 and renal insufficiency was given sufficient Paxlovid for 2 days and a half dose for 3 days. During treatment, the patient was complicated with lung infection and heart failure, and nucleic acid remained positive. After expert consultation, a full dose of Paxlovid was given again on the 9th day of admission for 2 days and a half dose for 3 days. Meanwhile, anti-heart failure and antibiotics were administered; the heart failure and pulmonary infection were improved. Finally, on the 33<sup>th</sup> day of admission, nucleic acid turned negative, body temperature returned to normal, cough and sputum, fatigue, poor appetite and other symptoms basically improved. The patient was given Paxlovid <i>via</i> nasal feeding for 2 courses without deterioration of liver and kidney function, diarrhea, nausea and vomiting, myalgia, chest tightness and other side effects, and was discharged from hospital with good recovery.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This case suggests that Paxlovid can be used cautiously in centenarians with renal insufficiency and two courses of treatment can be considered in patients with persistent positive nucleic acid.</AbstractText><CopyrightInformation>©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yi-Xue</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Juan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Hainan Chengmei Hospital, Haikou 570000, Hainan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chun-Yan</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Mei-Lan</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuan-Tao</ForeName><Initials>YT</Initials><AffiliationInfo><Affiliation>Department of Healthcare, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou 570208, Hainan Province, China. hyt951232@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>World J Radiol</MedlineTA><NlmUniqueID>101538184</NlmUniqueID><ISSNLinking>1949-8470</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Case report</Keyword><Keyword MajorTopicYN="N">Centenarians</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Lung infection</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">Renal insufficiency</Keyword></KeywordList><CoiStatement>Conflict-of-interest statement: The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>4</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39355387</ArticleId><ArticleId IdType="pmc">PMC11440271</ArticleId><ArticleId IdType="doi">10.4329/wjr.v16.i9.489</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76:e342–e349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Therapeutics and COVID-19: living guideline [Internet]. Geneva: World Health Organization, 2022 .</Citation><ArticleIdList><ArticleId IdType="pubmed">35917393</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardomi A, Khosroshahi HT. Dialysis-Induced Immune Dysregulations and Their Possible Impacts on COVID-19. Iran J Kidney Dis. 2021;15:161–167.</Citation><ArticleIdList><ArticleId IdType="pubmed">33994374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey A, Harris MA, Bogle D, Jama A, Muir SA, Miller S, Walters CA, Govia I. Coping With COVID-19: Health Risk Communication and Vulnerable Groups. Disaster Med Public Health Prep. 2021;17:e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8446589</ArticleId><ArticleId IdType="pubmed">34247692</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Zhang Y, Kang J, Chen Z, Peng M, Chen M, Zhang G, Xiang D, Xiao S, Li H, Mei Y, Yang J, Qi X, Cai D, Ren H. Weakened humoral and cellular immune response to the inactivated COVID-19 vaccines in Chinese individuals with obesity/overweight. Genes Dis. 2023;10:608–617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9707021</ArticleId><ArticleId IdType="pubmed">36466314</ArticleId></ArticleIdList></Reference><Reference><Citation>Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, Gerhart JL. Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:549–555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020856</ArticleId><ArticleId IdType="pubmed">35421077</ArticleId></ArticleIdList></Reference><Reference><Citation>Panda A, Arjona A, Sapey E, Bai F, Fikrig E, Montgomery RR, Lord JM, Shaw AC. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30:325–333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4067971</ArticleId><ArticleId IdType="pubmed">19541535</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L, Cottenet J, Mariet AS, Bonniaud P, Blot M, Tubert-Bitter P, Quantin C. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251–259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, Tie Y, Fullerton KE. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:759–765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;324:782–793.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386:1397–1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh A, Singh R, Misra A. Molnupiravir in COVID-19: A systematic review of literature. Diabetes Metab Syndr. 2021;15:102329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556684</ArticleId><ArticleId IdType="pubmed">34742052</ArticleId></ArticleIdList></Reference><Reference><Citation>Senderovich H, Vinoraj D, Stever M, Waicus S. Efficacy of COVID-19 treatments among geriatric patients: a systematic review. Ther Adv Infect Dis. 2022;9:20499361221095666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9168946</ArticleId><ArticleId IdType="pubmed">35677110</ArticleId></ArticleIdList></Reference><Reference><Citation>Catlin NR, Bowman CJ, Campion SN, Cheung JR, Nowland WS, Sathish JG, Stethem CM, Updyke L, Cappon GD. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M(pro) inhibitor in animal models. Reprod Toxicol. 2022;108:56–61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801796</ArticleId><ArticleId IdType="pubmed">35101563</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G, Zhang Y, Zhang H, Ai J, He L, Yuan X, Bao S, Chen X, Wang H, Cai J, Wang S, Zhang W, Xu J. Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave. Emerg Microbes Infect. 2022;11:2045–2054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448390</ArticleId><ArticleId IdType="pubmed">35924388</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>